» Articles » PMID: 11295656

Expression of IFN-gamma-inducible Protein; Monocyte Chemotactic Proteins 1, 3, and 4; and Eotaxin in TH1- and TH2-mediated Lung Diseases

Overview
Date 2001 Apr 11
PMID 11295656
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chemokines are involved in the influx of leukocytes into the airways in inflammatory lung diseases. The differential cell recruitment characteristic of T(H)1 versus T(H)2 immune responses may be associated with differential chemokine expression.

Objective: We investigated the expression of chemokines; monocyte chemotactic proteins (MCPs) 1, 3, and 4; eotaxin; and IFN-gamma-inducible protein 10 (IP-10) in both T(H)1- and T(H)2-mediated lung diseases.

Methods: By using immunocytochemistry and in situ hybridization, we examined the protein and mRNA expression, respectively, in bronchoalveolar lavage and biopsy samples in subjects with asthma, tuberculosis, sarcoidosis, and chronic bronchitis.

Results: Increased immunoreactivity and mRNA expression of IP-10 and of the MCPs was found in the bronchoalveolar lavage fluid and biopsy specimens of subjects with asthma and tuberculosis compared with that of control subjects (P <.005). IP-10, however, was particularly increased in subjects with sarcoidosis (P <.001). Eotaxin, on the other hand, was increased only in patients with asthma when compared with control subjects (P <.005).

Conclusion: This study demonstrates that MCP-1, MCP-3, and MCP-4 expression is not specifically associated with lung diseases characterized by a particular cytokine profile. In contrast, IP-10 is mostly expressed in T(H)1-mediated diseases, and eotaxin expression seems to be specifically associated with lung diseases of a T(H)2 cytokine profile.

Citing Articles

T1-T2 Interplay in the Complex Immune Landscape of Severe Asthma.

Gauthier M, Kale S, Ray A Immunol Rev. 2025; 330(1):e70011.

PMID: 39991821 PMC: 11849004. DOI: 10.1111/imr.70011.


Inflammatory plasma protein levels are elevated years before sarcoidosis diagnosis: a nested case-control study in Sweden.

Arkema E, Sachs M, Dominicus A, Eklund A, Smed-Sorensen A, Grunewald J Eur Respir J. 2024; 64(6).

PMID: 39326919 PMC: 11684420. DOI: 10.1183/13993003.00277-2024.


Increased serum interferon activity in sarcoidosis compared to that in tuberculosis: Implication for diagnosis?.

Schrijver B, Gopfert J, La Distia Nora R, Putera I, Nagtzaam N, Smits Te Nijenhuis M Heliyon. 2024; 10(18):e37103.

PMID: 39309852 PMC: 11416298. DOI: 10.1016/j.heliyon.2024.e37103.


Lung fibrosis in sarcoidosis. Is there a place for antifibrotics?.

Baczek K, Piotrowski W Front Pharmacol. 2024; 15:1445923.

PMID: 39281278 PMC: 11392764. DOI: 10.3389/fphar.2024.1445923.


Identifying the Interaction Between Tuberculosis and SARS-CoV-2 Infections via Bioinformatics Analysis and Machine Learning.

Huang Z, Kang J, Chen P, Deng L, Li J, He Y Biochem Genet. 2023; 62(4):2606-2630.

PMID: 37991568 DOI: 10.1007/s10528-023-10563-x.